Abstract
State of the art imaging of musculoskeletal (MSK) tumours includes conventional radiography (or CT in complex regions) and MRI of the local tumour and “whole body” modalities for staging. Whole body hybrid techniques with functional and anatomical information such as PET/CT are becoming increasingly available and can be expected to replace static staging modalities in certain indications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Parsons III TW, Filzen TW. Evaluation and staging of musculoskeletal neoplasia. Hand Clin. 2004;20:137–45.
“Der unerwartete Tumor aus interdisziplinärer Sicht” (The unexpected tumour from an interdisciplinary point of view). AMSOS – Austrian Musculoskeletal Oncology Society. Annual Meeting, Vienna, Nov 21–22; 2008
Lodwick GS. Solitary malignant tumours of bone: the application of predictor variables in gnosis. Semin Roentgenol. 1966;1:293–313.
Greenspan A, Jundt G, Remagen W. Differential diagnosis in orthopaedic oncology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
Lee T. Predicting failure load of the femur with simulated osteolytic defects using noninvasive imaging technique in a simplified load case. Ann Biomed Eng. 2007;35:642–50.
Edelstyn GA, Gillespie PJ, Grebbell FS. The radiological demonstration of osseous metastases: experimental observations. Clin Radiol. 1967;18:158–62.
Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–67.
de Kerviler E, Cuenod CA, Clement O, et al. What is bright on T1 MRI scans? J Radiol. 1998;79:117–26.
Van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Soft-tissue tumours: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology. 2004;233:493–502.
Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: a quantitative parameter for in vivo tumour characterization. Eur J Radiol. 2003;45:208–13.
Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by Proton MR Spectroscopy. Semin Musculoskelet Radiol. 2007;11:240–5.
Buhmann A, Baur-Melnyk S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. Am J Roentgenol. 2008;190:1097–104.
Wong KC, Kumta SM, Antonio GE, et al. Image fusion for computer-assisted bone tumor surgery. Clin Orthop Relat Res. 2008;466:2533–41.
Lassau N, Lamuraglia M, Vanel D, et al. Doppler us with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol. 2005;16:1054.
De Schepper AM, Vanhoenacker F, Gielen J, et al., editors. Imaging of soft tissue tumours. 3rd ed. Berlin: Springer; 2005.
Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49.
Eustace S, Tello R, DeCarvaiho V, et al. A comparison of whole-body TurboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. Am J Roentgenol AJR. 1997;169:1655–61.
Gilday DL, Ash JM. Benign bone tumours. Semin Nucl Med. 1976;6:33–46.
Mankin HJ. Chondrosarcoma of bone. In: Mendez LR, editor. Orthopedic knowledge update. Rosemont: American Academy of Orthopaedic Surgeons; 2002. p. 187–94.
Gates GF. SPECT bone scanning of the spine. Semin Nucl Med. 1998;28:78–94.
Savelli G, Maffioli L, Maccauro M, et al. Bonescintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37.
Homepage of Austin Hospital, Australia: http://www.petnm.unimelb.edu.au/pet/detail/clinical.html
Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET of primary benign and malignant bone tumours: standardized uptake value in 52 lesions. Radiology. 2001;219:774–7.
Shin D-S, Shon O-J, Han D-S. The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumours. Ann Nucl Med. 2008;22:603–9.
Bastiaannet E, Groen H, Jager PL. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101.
Aoki J, Endo K, Watanabe H, et al. FDG-PET for evaluating musculoskeletal tumours: a review. J Orthop Sci. 2003;8:435–41.
Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002;43:510–8.
Townsend DW, Beyer T, Blodgett TM, et al. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med. 2003;33:193–204.
Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242(2):360–85.
Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol. 2007;17:939–49.
Metser U, Lerman H, Blank A, et al. Malignant involvement of the spine: assessment by 18F-Fluorodeoxyglucose PET/CT. J Nucl Med. 2004;45:279–84.
Strobel K, Exner UE, Stumpe KDM, et al. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2008;35:2000–8.
Algra PR, Bloem L, Tissing H, et al. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics. 1991;11:219–32.
Avrahami E, Tadmor R, Dally O, et al. Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans. J Comput Assist Tomogr. 1989;13:598–602.
Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr. 1999;23:123–9.
Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18–2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumour staging in solid tumours: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.
Antoch G, Vogt FM, Bockisch A, et al. Whole-body tumour staging: MRI or FDG-PET/CT? [Article in German]. Radiologe. 2004;44:882–8.
Ito S, Kato K, Ikeda M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889–95.
Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36(Suppl 1):S113–20.
Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.
Peterson JJ. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumours. Semin Musculoskelet Radiol. 2007;11(3):246–60.
McCarville MB. New frontiers in pediatric oncologic imaging. Cancer Imaging. 2008;8:87–92.
Kajihara M, Sugawara Y, Sakayama K, et al. Evaluation of tumour blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy – work in progress. Radiat Med. 2007;25:94–105.
Even-Sapir E. PET/CT in malignant bone disease. Semin Musculoskelet Radiol. 2007;11:312–21.
Israel O, Goldberg A, Nachtigal A, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006;33:1280–4.
Clamp A, Danson S, Nguyen H, et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004;5:607–16.
Kazama T, Swanston N, Podoloff DA, et al. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406–11.
Menendez LR, Fideler BM, Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg Am. 1993;75(4):526–31.
Omlor G, Merle C, Lehner B, et al. CT-guided percutaneous radiofrequency ablation in osteoid osteoma: re-assessments of results with optimized technique and possible pain patterns in mid-term follow-up. Rofo. 2012;184(4):333–9.
Acknowledgments
We thank Teresa Zettl for the thorough administrative help.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 EFORT
About this entry
Cite this entry
Noebauer-Huhmann, I.M., Panotopoulos, J., Kotz, R.I. (2014). Imaging Algorithm in the Diagnosis, Therapy Control and Follow-up of Musculo-Skeletal Tumours and Metastases. In: Bentley, G. (eds) European Surgical Orthopaedics and Traumatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-34746-7_188
Download citation
DOI: https://doi.org/10.1007/978-3-642-34746-7_188
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-34745-0
Online ISBN: 978-3-642-34746-7
eBook Packages: MedicineReference Module Medicine